In this issue of Cancer Cell, Awad et al. report a phase 1b clinical trial combining a personalized vaccine NEO-PV-01 with chemotherapy and anti-PD-1 pembrolizumab in first-line metastatic non-squamous NSCLC. They demonstrate that this treatment regimen was well tolerated and induced neoantigen-specific CD4+ T cell responses with effector phenotype.
903 - 905
Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK. Electronic address: email@example.com.
Humans, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Vaccination, Clinical Trials, Phase I as Topic